In patients with mostly undifferentiated pleomorphic sarcomas, 2-year DFS with the addition of preoperative and postoperative pembrolizumab (Keytruda) infusions reached 67%, as compared with 52% with ...

A deep learning framework (DLF) to identify clinical predictors of disease progression and mortality in metastatic castration-resistant prostate cancer (mCRPC) patients treated with ...

An expert writes about his experience as a sarcoma medical oncologist and how the field may progress with several therapies in the pipeline. As a sarcoma medical oncologist, the No. 1 question I am ...

The following represents disclosure information provided by authors of this manuscript. All relationships are considered compensated unless otherwise noted. Relationships are self-held unless noted. I ...

In part 3 of an interview, MD Anderson’s Ravin Ratan, MD, MEd, discusses neoadjuvant immune checkpoint blockade for 2 specific types of soft tissue sarcomas. Liposarcomas originate in fat cells and ...

Success rates for drug development in solid tumors remain the lowest of the many therapeutics areas in medicine. Recent advances in drug discovery and development have transformed available therapies ...

When surgery is part of the treatment plan, choosing a team with deep sarcoma-specific surgical experience is one of the most important decisions a patient can make. With more than 70 distinct sarcoma ...

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com. A 56-year-old man presented to the ED with 3 months of ...

Please provide your email address to receive an email when new articles are posted on . A phase 2 trial conducted by researchers at The University of Texas MD Anderson Cancer Center demonstrated the ...

Immune checkpoint blockade therapy works by preventing the binding of checkpoint and partner proteins, thereby allowing T cells to continue their work of attacking and killing cancer cells. A team ...